

wherein X_1 is Gln, or Ala; X_2 is Trp or Leu; X_3 is Gln, Lys, Orn, Ala, or Nle; X_4 is Arg, Lys, Ala; X_5 is Asn, Orn, Ala, or Nle; X_6 is Met or Leu; and X_7 is Arg or Lys, or a functionally equivalent homolog or analog of the peptide, and wherein SEQ ID NO: 38 is excluded.

55. (New) The peptide of claim 54, wherein the peptide is SEQ ID NO: 70, 72, 73, 74, 80-83, 87-91, 93-95 or 97.

56. (New) The peptide of claim 54, wherein X_1 is Q and X_5 is N.

57. (New) The peptide of claim 54, wherein the peptide further comprises GPPVSCIKR at the carboxy terminus or a functionally equivalent homolog or analog of the peptide.

58. (New) The peptide of claim 54, wherein the peptide further comprises TK or EATK at the amino terminus of the peptide.

59. (New) The peptide of claim 57, wherein the peptide further comprises TK or EATK at the amino terminus of the peptide.

60. (New) The peptide of claim 54, wherein the peptide is cyclised through a disulfide bridge or a functionally equivalent homolog or analog of the peptide.

61. (New) The peptide of claim 55, wherein the peptide further comprises GPPVSCIKR at the carboxy terminus or a functionally equivalent homolog or analog of the peptide.

62. (New) The peptide of claim 55, wherein the peptide further comprises TK or EATK at the amino terminus of the peptide.

63. (New) The peptide of claim 61, wherein the peptide further comprises TK or EATK at the amino terminus of the peptide.

64. (New) The peptide of claim 61, wherein the peptide is cyclised through a disulfide bridge or a functionally equivalent homolog or analog of the peptide.

65. (New) The peptide of claim 54, wherein the N-terminal amino acid of the peptide is acetylated and/or amidated.

66. (New) The peptide of claim 54, wherein the cysteine is replaced by an acetamidomethyl-cysteine, or a functionally equivalent homolog or analog of the peptide.

67. (New) The peptide of claim 54, wherein the peptide comprises any of SEQ ID NOS: 68-96.

68. (New) The peptide of claim 55 comprising SEQ ID NO: 70 or 74.

69. (New) The peptide of claim 55 comprising SEQ ID NO: 81 or 83.

70. (New) The peptide of claim 55 comprising SEQ ID NO: 87 or 89.

71. (New) The peptide of claim 55 comprising SEQ ID NO: 91.

72. (New) A peptide of claim 54, wherein the peptide has a capped C-terminus.

73. (New) The peptide of claim 72, wherein the peptide is SEQ ID NO: 47 or 92.

74. (New) A peptide of claim 72, wherein the peptide further has a capped N-terminus.

75. (New) A medicinal product comprising a peptide of claim 54.
76. (New) A medicinal product comprising a peptide of claim 55.
77. (New) The medicinal product of claim 75 for treatment and/or prevention of infections and/or inflammations.
78. (New) The medicinal product of claim 77 for treatment and/or prevention of a urinary tract infection.
79. (New) The medicinal product of claim 77 for treatment and/or prevention of colitis.
80. (New) The medicinal product of claim 77 for treatment of a candida infection on a mucosal membrane.
81. (New) The medicinal product of claim 75 formulated for parenteral administration.
82. (New) The medicinal product of claim 75 formulated for oral administration.
83. (New) The medicinal product of claim 75 formulated for topical administration.
84. (New) The medicinal product of claim 83 formulated for administration on mucosal membranes.
85. (New) A food stuff comprising a peptide of claim 54.

86. (New) The food stuff of claim 85, wherein the food stuff is an infant formula food.

87. (New) A method of treating or preventing infections or inflammations comprising administering to a patient in need thereof an effective amount of a peptide of claim 54.

88. (New) A method of treating or preventing infections or inflammations comprising administering to a patient in need thereof an effective amount of a peptide of claim 55.

89. (New) The method of claim 87, wherein the infection is an urinary tract infection.

90. (New) The method of claim 87, wherein the inflammation or infection is colitis.

91. (New) The method of claim 87, wherein the infection is a candida infection on a mucosal membrane.

92. (New) The method of claim 87, wherein the peptide is administered orally.

93. (New) The method of claim 87, wherein the peptide is administered parenterally.

94. (New) The method of claim 87, wherein the peptide is administered topically.

95. (New) The method of claim 94, wherein the peptide is administered on mucosal membranes.

96. (New) The method of claim 92, wherein the peptide is administered orally in a food stuff.

97. (New) The method of claim 96, wherein food stuff is an infant formula food.

